東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Advances in host-directed therapies ...

Karakousis, Petros C.

FindBook

Google Book

Amazon

博客來

Advances in host-directed therapies against tuberculosis

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Advances in host-directed therapies against tuberculosis/ edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
其他作者:	Karakousis, Petros C.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	xiii, 332 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Immunotherapy - Methods. -
電子資源:	https://doi.org/10.1007/978-3-030-56905-1
ISBN:	9783030569051

Advances in host-directed therapies against tuberculosis
Advances in host-directed therapies against tuberculosis[electronic resource] /edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro. - Cham :Springer International Publishing :2021. - xiii, 332 p. :ill., digital ;24 cm.

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT) The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

ISBN: 9783030569051

Standard No.: 10.1007/978-3-030-56905-1doiSubjects--Topical Terms:

3488335
Immunotherapy
--Methods.

LC Class. No.: RC311.3.C45

Dewey Class. No.: 616.995

Advances in host-directed therapies against tuberculosis
LDR:02166nmm a2200313 a 4500 001 2236700
003 DE-He213
005 20201203214622.0
006 m d
007 cr nn 008maaau
008 211111s2021 sz s 0 eng d
020 $a 9783030569051 $q (electronic bk.)
020 $a 9783030569044 $q (paper)
024 7 $a 10.1007/978-3-030-56905-1 $2 doi
035 $a 978-3-030-56905-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC311.3.C45
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.995 $2 23
090 $a RC311.3.C45 $b A244 2021
245 0 0 $a Advances in host-directed therapies against tuberculosis $h [electronic resource] / $c edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xiii, 332 p. : $b ill., digital ; $c 24 cm.
520 $a This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT) The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.
650 0 $a Immunotherapy $x Methods. $3 3488335
650 1 4 $a Immunology. $3 611031
650 2 4 $a Infectious Diseases. $3 894100
650 2 4 $a Pharmacotherapy. $3 1978501
650 0 $a Tuberculosis $x Immunotherapy. $3 3488334
700 1 $a Karakousis, Petros C. $3 3488331
700 1 $a Hafner, Richard. $3 3488332
700 1 $a Gennaro, Maria Laura. $3 3488333
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-56905-1
950 $a Biomedical and Life Sciences (SpringerNature-11642)